• Self-quarantine Has Leveled the Social Playing Field
  • NORD’s Advice on COVID-19: You’re Stronger Than You Think
  • MDA Hosting Online Q&A on COVID-19 Today
  • Trial Use of Edasalonexent Not Likely to Raise COVID-19 Risk, Catabasis Reports
  • Make the Most Out of Your Time – Lockdown Tips
  • The Muscular Dystrophy Community Counts on Accessibility Improvements
  • Phase 1 Results Support Losmapimod as FSHD Treatment
  • NORD Partners with ‘Sing Me a Story’ for July 18–20 Living Rare Forum
  • Sarepta Working to Ensure Treatment Access, Clinical Trials Continuity Amid COVID-19 Pandemic
  • Emflaza Supply Not Affected by COVID-19 Pandemic, PTC Therapeutics Says
  • Global Rare Disease Group’s Focus: 1,000 New Therapies by 2027, Despite COVID-19
  • Viltolarsen Available to U.S. DMD Patients Under Expanded Access Program